Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial.

Lau Yu-Lung,Nelson E Anthony S,Poon Kin-Hung,Chan Paul K S,Chiu Susan,Sung Rita,Leung Chi Wai,Ng Daniel, Ma Yee Man,Chan Desmond,Lee Tsz Leung,Tang Joyce,Kwan Yat Wah, Ip Patricia,Ho Marco,Fung Lai-Wah Eva,Tang Haiwen,Suryakiran P V,Han Htay Htay,Bock Hans, Null Null

Vaccine（2013）

引用 20|浏览31

暂无评分

摘要

•Efficacy, immunogenicity and safety of RIX4414 vaccine in Hong Kong infants.•Randomized double-blind, placebo-controlled study of 3025 infants.•Vaccine efficacy against severe RVGE was 95.6% (<2 years) and 96.1% (<3 years).•No safety concern was identified.

查看译文

关键词

ARSN,ATP,CCID50,DTPa,DTPw,ELISA,GMCs,Hib,ICD,IPV,OPV,RT-PCR,RVGE,SAE,U/mL,WHO

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要